Sahil has extensive expertise in building bio-pharma pipelines and executing commercial strategies. He joined the atai leadership team in 2022. He leads the portfolio strategy, business development, early commercialization and corporate communication functions.

Previously, Sahil held multiple senior leadership positions at Otsuka Pharmaceutical Co., Ltd. for over eight years, where he built a successful pipeline in CNS, nephrology and oncology, closed more than USD 2.7 billion in transactions and worked on the successful commercial launch of multiple drugs. Throughout his career he has worked across geographies and markets in large and small companies – setting up teams and offices across the world, including London, Singapore and Shanghai.

He is a trained physician and holds an MPhil from the University of Cambridge (where he is subsequently an honorary lecturer).